Key result
Female sex was associated with worse AF symptom severity (MD 0.29; 95% CI 0.07-0.52), and rate control therapy was associated with lower quality of life (MD -7.22; 95% CI -11.51 to -2.92).
Why the study?
Women report higher AF symptom severity and receive fewer AF therapies than men, but whether differences in therapies explain sex differences in symptom severity is understudied.
Do sex and AF therapies impact patient-reported outcomes in patients with atrial fibrillation?
Observational (n=953)
Yes
Do sex and AF therapies impact patient-reported outcomes in patients with atrial fibrillation?
Mean Difference: 0.29 (95% CI 0.07–0.52)
Female sex is associated with worse AF symptom severity and quality of life independent of AF therapies received, while rate control alone is associated with poorer quality of life and functional status.
No takes yet. Share an insight, caveat, or question.
Rate control linked to poorer AF QoL in Level 4 data; hypothesis-generating and should not yet change practice.
Gleason et al. (2019) conducted an observational in Atrial fibrillation (n=953). Female sex and rate control therapy vs. Male sex and alternative/no therapies was evaluated on AF symptom severity (MD 0.29, 95% CI 0.07 to 0.52). Female sex was associated with worse AF symptom severity (MD 0.29; 95% CI 0.07-0.52), and rate control therapy was associated with lower quality of life (MD -7.22; 95% CI -11.51 to -2.92).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: